For patients with piriformis syndrome whose buttock and sciatic pain persists after an initial treatment course, a structured next-line protocol addresses the gap when earlier approaches fall short of full symptom resolution.
This protocol applies when a prior course — including gabapentin or pregabalin, ultrasound-guided dry needling, triple acupuncture, or neural therapy — did not produce complete resolution of buttock and sciatic pain, did not restore hip range of motion, or did not sufficiently reduce disability by the end of the treatment period.
Success is measured by meaningful pain relief at 1 week and 1 month post-injection, reflected in improvement across validated pain scales from baseline.
DOI: 10.5812/aapm.112825
Steroid injections are saved for patients who fail to respond to conservative treatment, NSAIDS, or physical therapy.
In 2019, a cohort of 32 patients with piriformis syndrome was injected with 4 mL of lidocaine 2% and 1 mL of betamethasone in the piriformis muscle while using ultrasound guidance.
Forty-nine patients with deep gluteal syndrome were given a mixture of 20 mL of saline, 4 mL of 2% lidocaine, and 1 mL of a corticosteroid (40 mg of methylprednisolone acetate) in the perisciatic region between the gluteus maximus and pelvitrochanteric muscles.
The patients showed a statistically significant improvement in all three pain scales used from baseline to one month (P < 0.001) and in two of the three pain scales from one week to one month (P < 0.001).
Of the 49 patients, 73.7% reported some level of pain relief the average pre-injection pain score being 8.3 and the average post-injection pain score being 2.8.
View source ↗